|
Hormone |
Treatment |
Admission (A) |
End of Month 1 |
End of Month 2 |
End of Month 3 |
End of Month 4 |
SED |
Placebo |
Maca |
SED |
P |
|
FSH (mIU/ml) |
APPMM |
64.62 |
70.54 |
71.28 |
65.6 |
60.66 |
8.08 |
70.91 |
63.56 |
5.6 |
ns |
|
AMMPP |
69.03 |
62.01 |
57.27 |
53.63 |
59.22 |
7.465 |
56.42 |
59.64 |
5.29 |
ns |
|
|
SED |
|
17.301 |
17.348 |
17.371 |
19.208 |
16.565 |
15.618 |
|
|
||
|
P |
|
ns |
ns |
|
|
|
ns |
ns |
|
|
|
|
E2 (Pg/ml) |
APPMM |
19.11 |
8.33 |
15.14 |
45.72 |
58.43 |
22.195 |
11.73B |
50.95A |
15.36 |
<0.05 |
|
AMMPP |
8.62 |
12.08 |
25.3 |
25.61 |
17.14 |
21.602 |
21.13 |
18.69 |
15.05 |
ns |
|
|
SED |
|
31.661 |
28.375 |
29.016 |
35.96 |
18.992 |
19.124 |
|
|
||
|
P |
|
ns |
ns |
ns |
Ns |
|
ns |
ns |
|
|
|
|
PRG (ng/ml) |
APPMM |
0.201 |
0.203 |
0.213 |
0.277 |
0.286 |
0.232 |
0.208 |
0.282 |
0.176 |
ns |
|
AMMPP |
0.224 |
0.233 |
0.373 |
0.281 |
0.252 |
0.281 |
0.266 |
0.303 |
0.125 |
ns |
|
|
SED |
|
0.429 |
0.425 |
0.224 |
0.261 |
0.172 |
0.148 |
|
|
||
|
P |
|
ns |
ns |
ns |
ns |
|
ns |
ns |
|
|
|
|
LH (mIU/ml) |
APPMM |
43.79 |
38.92 |
38.91 |
34.05 |
32.41 |
3.985 |
38.91A |
33.38B |
2.74 |
<0.05 |
|
AMMPP |
36.66 |
32.69 |
32.58 |
30.03 |
32.5 |
3.678 |
31.27 |
32.64 |
2.59 |
ns |
|
|
SED |
|
8.6 |
8.566 |
8.622 |
8.805 |
6.203 |
6.035 |
|
|
||
|
P |
ns |
ns |
ns |
Ns |
ns |
ns |
|||||
|
1 For explanation see Table 1. SED, Standard error of differences; P, Probabilities of significance. ns, not significant at P>0.05; <0.05, significance at 5% probability level; <0.01, significance at 1% probability level; <0.001, significance at 0.1% probability level. |
|||||||||||